Currently,the only potential curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (allo-HSCT),whose status is not moved in spite of the widespread using of hypomethylating agents (HMAs).Several prognostic scoring systems can be used for selecting candidates for alloHSCT.No conclusive evidence establishes that HMAs used as bridge treatment for modifying tumor burden prior to transplant can improve prognosis,thus an intended transplantation shouldn\'t be delayed for waiting for the effects of HMAs.Several retrospective studies have demonstrated the benefit of HMAs in prevention or treatment of relapse after allo-HSCT,though further evidence is needed.As haploidentical HSCT has a similar efficacy with matched HSCT in MDS treatment,the problem of lack of donor is settled in a degree.So this therapeutic method would attract more study interest and be applied more broadly.